Elevated urine neutrophil gelatinase-associated lipocalin can diagnose acute kidney injury in patients with chronic kidney diseases  by Sise, Meghan E. et al.
Elevated urine neutrophil
gelatinase-associated lipocalin
can diagnose acute kidney injury
in patients with chronic kidney
diseases
Kidney International (2009) 75, 115–116; doi:10.1038/ki.2008.529
To the Editor: Hsu et al. evaluated the association between
chronic kidney disease (CKD) and risk of acute kidney injury
(AKI). They demonstrated several important findings: (1)
CKD is an important risk factor for the development of AKI;
(2) even early CKD stage 3 kidney dysfunction is a risk factor
for the development of AKI; and (3) AKI risk increased in a
step-wise relationship with worsening kidney disease.1 The
public health implication of their investigation is immense.
In 2000, 20 million adults in the United States were affected
by kidney disease,2 and as the prevalence of CKD increases,
the incidence of AKI will also continue to increase.3
An important issue concerning the diagnosis of AKI is that
the clinical standard, the serum creatinine, is a suboptimal
method to evaluate AKI in CKD. In the setting of CKD,
serum creatinine levels are already elevated and may fall in
advanced disease secondary to changes in extrarenal
clearance.1,4,5 Furthermore, serum creatinine levels are
known to vary as a function of muscle mass, gender, race,
medications, and comorbid conditions. Given these well-
known limitations, it is not surprising that Hsu et al.1 found
that serum creatinine cannot distinguish between natural
progression of CKD and acute-on-chronic disease.
Neutrophil gelatinase-associated lipocalin (NGAL) is a
biomarker of AKI. We recently demonstrated in a large-scale
prospective trial that a single spot urine NGAL is able to
predict the subsequent development of AKI on presentation
to the emergency department (ED).6 We conducted a
secondary data review of this cohort to determine the
characteristics of NGAL in all patients with CKD, with and
without AKI.
We included all-comers to the ED in order to enroll a
representative sample of women, racial/ethnic minorities,
and patients without insurance. CKD was defined according
to the National Kidney Foundation Chronic Kidney Disease
guidelines (estimated glomerular filtration rate (eGFR)
o60 ml/min). The modified Modification of Diet in Renal
Disease was used to determine eGFR.7 Baseline kidney
function was determined by reviewing electronic medical
records for serum creatinine measurements between 1 and
12 months before ED presentation. AKI was defined
according to minimal risk, injury, failure, loss, end-stage
(RIFLE) criteria established by the Acute Dialysis Quality
Initiative.8
Table 1 demonstrates our findings. A total of 156 patients
were enrolled with an eGFR o60 ml/min, of these 15 (10%)
developed AKI. On average, patients with CKD who
developed AKI were significantly younger and more likely
to be of black race. In agreement with Hsu et al., patients
with CKD who developed AKI had significantly worse
baseline kidney function than those patients who did not
develop AKI (27.5±13.0 vs 41.2±12.7 ml/min; P-value
o0.001 for AKI and non-AKI groups, respectively). Spot
urine NGAL levels at ED presentation were significantly
higher in those patients with CKD who developed AKI
(434.6±233.1 vs 21.9±36.9 mg/g; P-value o0.001, respec-
tively). In our series, six patients (40%) with AKI on CKD
required inpatient hemodialysis.
These data strongly suggest that in the setting of CKD,
elevated urine NGAL levels are associated with the develop-
ment of AKI. Therefore, in patients with CKD, urine NGAL
may provide both a rapid diagnosis of AKI and differentiate
AKI from changes in GFR due to chronic disease progression.
Early and rapid AKI diagnosis in this patient population
will allow for appropriate triage (to admit or discharge
the patient) and avoidance of potentially nephrotoxic
medications.
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Table 1 | Patient characteristics
Characteristic Acute injury on CKD (n=15) Stable CKD (n=141) P-value
Mean age (s.d.) (years) 57.3 (13.6) 69.8 (15.4) 0.003
Women (%) 66.7 56.7 0.6
Black race (%) 53.3 25.5 0.03
Mean baseline eGFR (s.d.) (ml/min per 1.73 m2) 27.5 (13.0) 41.2 (12.7) o0.001
Mean ER eGFR (s.d.) (ml/min per 1.73 m2) 15.3 (8.3) 37.4 (14.6) o0.001
Mean NGAL level (s.d.) (mg/g creatinine) 434.6 (233.1) 21.9 (36.9) o0.001
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NGAL, neutrophil gelatinase-associated lipocalin.
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We thank Dr. Sise and co-workers very much for their
letter and interest in our recent publication.1 We
appreciate them sharing their stratified analysis among
the subset of their patients with chronic kidney disease
from their provocative study.2
We would like to make a clarification regarding the
statement ‘it is not surprising that Hsu et al. found that
serum creatinine cannot distinguish between natural pro-
gression of CKD and acute-on-chronic disease.’ What we
had said was that ‘Among patients with very advanced
chronic kidney disease, it may be difficult to distinguish
between the final stages of progression to end-stage renal
disease from potentially reversible acute-on chronic renal
failure so the very high odds ratio observed among
those with estimated GFR of o15 ml per min per 1.73 m2
must be interpreted with caution.’1 Using direct medical
records review of a random sample of 100 patients with
baseline estimated GFR o45 ml/min per 1.73 m2, we
demonstrated that we were able to identify accurately cases
of acute-on-chronic kidney disease. As described in the
paper, a board-certified nephrologist confirmed that 100% of
the time, our algorithm captured true cases of acute renal
failure/acute kidney injury and did not mistakenly include
cases of progression of chronic kidney disease. The etiology
of these 100 cases of acute on chronic renal failure are
shown below and are comparable to that reported in prior
studies.3
We agree completely that neutrophil gelatinase-
associated lipocalin and other biomarkers are an exciting
area of research in acute kidney injury. Currently these
biomarkers are being validated against ‘gold standard’
definitions of acute kidney injury as determined by
changes in serum creatinine.2,4,5 Our understanding of
the epidemiology of acute kidney injury and the role of
biomarkers should be greatly enhanced with the antici-
pated launch of the NIH-NIDDK sponsored study of the
natural history of acute kidney injury (http://grants.
nih.gov/grants/guide/rfa-files/RFA-DK-07-009.html).
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To the Editor: Ahmed et al1 investigate a facet of
postmenopausal hormone therapy (HT) hereunto unad-
dressed by the Women’s Health Initiative, but their
epidemiologic approach raises several questions.
The authors chose age 66 as the minimal age for
enrollment (mean age 470), and subjects were largely
plagued by various chronic ailments and renal compromise
(estimated glomerular filtration rate o90 ml/min per
1.73 m2). As younger (o age 60) women with normal renal
function account for the overwhelming majority of HT
utilization, why did the investigators select a markedly
Etiology
Decreased renal perfusion (including volume contraction,
congestive heart failure, hypotension, cardiac arrest)
76
Medication related 0
Radiocontrast media 6
Postoperative 6
Sepsis 21
Others 6
Total exceeds 100 as some cases had more than one contributing etiology
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